ENGINEERED PROTEINS TO REPAIR OR REGROW DAMAGED HEART MUSCLE CELLS AND TISSUE
Associate Professor Dan Hesselson,
Head of the Centre for Biomedical AI,
Centenary Institute
Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | July 2026
Associate Professor Dan Hesselson leads the Centre for Biomedical AI at the Centenary Institute.
He is an internationally trained research leader in regenerative medicine, focusing on cells and organs affected by heart disease, diabetes and cancer. His work uses insights from the study of basic regenerative processes to identify novel therapeutic targets for these devastating diseases.
His work with zebrafish, which started at University of California San Francisco (UCSF) and was expanded at the Garvan Institute, made significant contributions to our understanding of the molecular mechanisms of regeneration in this highly regenerative model system.
At the Centenary Institute, he is focused on exploiting these breakthroughs in basic science to develop new therapeutic strategies using the power of Directed Evolution to generate potent and highly specific biologic drugs.
His research is investigating new ways to repair the heart and improve outcomes for individuals recovering from heart attacks or living with heart disease, aiming to address a critical gap in cardiac care.
While current treatments can manage symptoms, they cannot restore heart function once muscle cells are lost. This irreversible damage is why heart failure remains a leading cause of death worldwide.
Associate Professor Hesselson’s research aims to address this challenge by developing therapies based on engineered proteins capable of repairing or regrowing damaged heart muscle cells and tissue.
Source: Supplied and adapted from Centenary Institute media release (June 2026)
-
Healthcare associated infection prevention
Professor Philip Russo is an internationally regarded expert in healthcare associated infection prevention, and led the recently completed the Australian National Healthcare Associated Infection Point Prevalence Survey, the first in Australia for 34 years. He is also Past President of the Australasian College for Infection Prevention and Control (ACIPC), the peak body for Infection Prevention and Control professionals in the Australasian region.
-
Earlier identification and early intervention for children who are deaf or hard of hearing
As Director of NextSense Institute, Professor Leigh is responsible for leading the not-for-profit organisation’s world-class research and education programs and facilities. He has held a variety of positions in the education of children who are deaf or hard of hearing before entering academia. He holds a degree in Special Education from Griffith University, a Master of Science (Speech and Hearing) from Washington University and a PhD in Special Education from Monash University. In 2001, he was made a Fellow of the Australian College of Educators and in 2014, he was invested as an Officer in the Order of Australia (AO) for distinguished services to the deaf and hard of hearing community.
-
Digital Biomarkers and AI for Optimal Diagnosis, Treatment, and Decision-Making
Associate Professor Johan Verjans is a clinician-scientist with a strong focus on cross-disciplinary translational research. In his role as Deputy Director at the Australian Institute for Machine Learning (AIML)—one of the world’s premier machine learning institutes, with over 200 researchers—and as Group Leader of Artificial Intelligence at the South Australian Health and Medical Research Institute (SAHMRI), he integrates his expertise in molecular medicine, clinical research, and advanced imaging with machine learning applications. This unique combination enables him to drive the translation of cutting-edge AI research into practical medical applications. He works with global teams from multinationals on AI problems.
